News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ablexis Maps Out New Antibody Drug Strategy with $12M From Third Rock Ventures, Pfizer Inc. (PFE)


6/23/2010 7:17:56 AM

Xconomy -- Antibodies that can zero in on specific diseased cells are some of biggest-selling and fastest-growing fields in all of biotech. Yet after three decades of R&D, if you talk to people who try to discover these things, they’ll tell you it’s a long and risky slog to get any good candidates for clinical trials. San Francisco-based Ablexis is betting that it has created a more effective way to generate promising antibodies, and revamped its business model to try to generate real cash.

Read at Xconomy

comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES